A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

NCT06804603 · Completed

Last updated 2026-05-28

This clinical trial is testing whether tradipitant can reduce nausea and vomiting in adults with obesity who are using GLP-1 receptor agonist medications.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 124 people

Who can join Ages 18–65 · all sexes

Timeline Started 2025-02 · est. completion 2025-10

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT06804603 ↗

Description as written by the study sponsor.

The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.

Treatments tested

Tradipitant Drug

Oral capsule
Placebo Drug

Oral capsule

Main thing measured	Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary.
Sponsor	Vanda Pharmaceuticals
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06804603 ↗